Curacle is a clinical-stage biotech that does not sell finished products; instead it develops new drugs, proves them in clinical trials, and then licenses the rights out to pharmaceutical companies. Its lead program is CU06, a First-in-Class oral candidate that targets vascular endothelial dysfunction and is being developed for diabetic macular edema and wet age-related macular degeneration, aiming to be a pill rather than an eye injection. The company has broadened its pipeline into kidney disease and antibodies (the MT series), and 2025 revenue was roughly ₩7.1 million, effectively near zero. In April 2026 it disclosed the clinical-study report (CSR) for its Phase 2b diabetic nephropathy candidate CU011001, and in May it signed an out-licensing deal for the bispecific antibody MT-103; CU06 discussed its Phase 2b/3 strategy with the FDA at a Type C meeting in February. What stands out recently is that its diversified pipeline (rather than a bet on a single candidate), its First-in-Class oral drug, and the MT-103 licensing track record are strengths, while the absence of any marketed product means revenue and profit swing with the timing of deals, large annual operating losses are funded by R&D spending, and additional financing and share-count increases are a constant possibility, so this name is best followed by tracking clinical timelines and deal flow rather than earnings figures.
At-a-glance assessment financial health · growth · profitability · valuation
- The most recent full-year net result was a loss.
- Revenue fell 99.6% year over year (3-year trend: falling).
- ROE is -48.8% (total-net basis). It is below the sector average.
- Operating margin is -232393.8%.
- P/E is hard to compute here, so this is read on P/B.
Ownership & governance As of 2025-12-31
Largest shareholder Kwon Young-geun 8.62% (individual)
Controlling bloc incl. related parties 8.93%
With the controlling bloc holding 9%, ownership is dispersed, leaving room for control-related or activist dynamics.
🔎 In-depth analysis
- Curacle is not a company that makes money by selling finished products; it is a clinical-stage biotech that develops new drugs itself, demonstrates their efficacy in trials, and then licenses those rights out to pharmaceutical companies (out-licensing).
- Its core is CU06, a First-in-Class (essentially a world-first for its mechanism) oral candidate targeting vascular endothelial dysfunction, with diabetic macular edema and wet age-related macular degeneration as its indications.
- Its biggest differentiator is that it aims to be a pill with a different mechanism of action from existing eye injections (Anti-VEGF).
- On top of this, it has broadened its pipeline across ophthalmology, kidney disease, and antibodies with the diabetic nephropathy candidate CU01 (CU011001), single and bispecific antibodies developed together with the antibody specialist Maptix (MT-101, MT-103, MT-201, MT-202), and a companion-animal kidney disease program (CP01).
- The reason 2025 revenue was roughly ₩7.1 million, effectively near zero, is that it has no marketed product yet and its income depends on licensing upfront payments and milestones (success-based payments at each stage).
- For a company like this, it is truer to its nature to look at how far the pipeline has advanced rather than how much profit it made this year.
- The latest close is ₩9,540 and the market cap is ₩211.4 billion.
- The price sits below both its 20-day line (₩12,180) and its 60-day line (₩13,914).
- Trading below both its short- and mid-term moving averages, the trend is on the soft side.
- Its RSI (a supplementary gauge comparing upward and downward strength over the past 14 days on a 0-100 scale) is 32.8, a neutral level.
- It is down 15.3% over one month and 28.4% over three months, and stands 51.6% below its 52-week high.
- Its relative strength versus the KOSDAQ is 86 (1-99, computed from returns against the index over the past year with more weight on recent performance; higher means stronger than the market).
- That places it in roughly the top 13% of all stocks by strength.
- Over the past three months it lagged the index by 6.3%.
- Chart readings are best interpreted alongside trading volume and disclosure dates.
- Judged by the yardstick of an ordinary manufacturer, almost every metric looks poor, but for a clinical-stage biotech pouring money into R&D without revenue, that in itself is not abnormal.
- The P/E ratio (how many times one year's profit the share price is) cannot be calculated because it is loss-making, and EPS (net profit per share) is -₩820.6.
- The P/B (how many times net assets the share price is) is 5.68x, and it is natural for an R&D company without many assets to look high when viewed on net assets alone.
- But this figure is more accurately read as the share price pricing in the future pipeline value the market expects, rather than meaning the stock is expensive.
- In fact, the P/B being formed at no higher a level than peers can be seen as a signal that there is no excessive froth in the share price relative to the assets it holds.
- ROE (how much it earns in a year on its equity) and its operating and net margins being deeply negative also stem from spending R&D money in a state of almost no revenue, not from a broken business.
- Its debt ratio (debt to equity) is 143% and its current ratio (assets readily convertible to cash versus debt due within a year) is 192%, so short-term solvency itself is not precarious.
- That said, convertible bonds remain outstanding (a conversion-price adjustment was disclosed), and if converted they could increase the share count, which is worth watching.
- In short, the financials should be read not as a company that cannot make money, but as one that has not yet reached the stage of making it.
- Revenue swung sharply year to year, from roughly ₩10.3 billion in 2023 to about ₩1.6 billion in 2024 and roughly ₩7.1 million in 2025.
- This is not because the business faltered but simply the difference between years when licensing upfront payments came in and years when they did not, a common irregular pattern in clinical-stage biotech.
- Operating and net losses arise every year from the investment needed to push candidates into later-stage trials (2025 net loss of roughly ₩18.1 billion), and in Q1 2026 the loss-making structure continued with revenue of roughly ₩1.05 billion and a net loss of roughly ₩3.1 billion.
- One thing should be made clear here.
- The reason a forward (this-year estimate) profit figure cannot be pinned down for this name is not that the estimate is flimsy, but that with no marketed product the timing of a swing to profit itself depends on the clinical schedule.
- Accordingly, neither the trailing P/E (based on last year's confirmed results) nor the forward P/E (based on this year's estimate) can be captured as a meaningful figure right now, and this is normal rather than a weakness to be marked down.
- Instead, growth must be gauged by CU06's clinical progress and FDA discussion stage and by subsequent out-licensing deals, and by that measure the traces of progress are actually accumulating, such as the discussion of CU06's Phase 2b/3 development strategy and the signing of the MT-103 license.
- Recent developments converge on the two pillars of the biotech's core business: clinical data and out-licensing.
- In April 2026 a disclosure related to the Phase 2b clinical-study report (CSR) for the diabetic nephropathy candidate CU011001 secured later-stage clinical data for the kidney indication, and in May the signing of an out-licensing deal for the bispecific antibody MT-103 was disclosed, marking the first external licensing result for its in-house antibody pipeline (with detailed terms supplemented via a June amendment).
- Over the same May-June period, a convertible-bond conversion-price adjustment, changes in holdings by executives and major shareholders, and a stock-option grant filing followed in succession; the convertible bonds and stock options are traces of financing and talent acquisition while also being two-sided factors that could lead to a higher share count in the future.
- According to the company's own materials, CU06 discussed its development strategy through Phase 2b/3 at an FDA Type C meeting in February, and following MT-103 it is also exploring further collaboration on MT-201 and MT-202.
- The strengths are clear.
- Curacle has spread its pipeline across ophthalmology (CU06), kidney disease (CU01), and antibodies (the MT series) rather than leaning on a single candidate, and CU06 targets a large indication market (about ₩26 trillion in 2025 by the company's own estimate) with the differentiators of being a pill rather than an injection and First-in-Class.
- Having a track record of turning candidates into actual deals, as with the MT-103 license, is no small strength in drug-development biotech.
- On valuation too, it is hard to see excessive froth in the share price relative to the assets it holds.
- At the same time, the cautions deserve an honest look.
- With no marketed product, revenue and profit are uneven depending on deal timing, and the structure of covering large annual operating losses with R&D funding means additional financing and the resulting share-count increases are a constant.
- Because the cost of failure or delay grows the later a trial goes, the readout of any trial can move the share price sharply.
- In short, this name has the classic character of a clinical-stage biotech: strong when clinical progress and out-licensing go smoothly, weak when clinical setbacks or financing strain come to the fore.
- That is why the proper way to read this company is to follow its clinical timelines and deal flow rather than its earnings figures.
🔎 Valuation vs peers Inconclusive
Compared against the group of domestic clinical-stage drug-development biotechs whose value is set by pipeline clinical stage and out-licensing results rather than by a marketed product (a homogeneous group where a profit-based P/E comparison does not hold).
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Curacle | 0.00x | 5.68x | -48.84% |
Because Curacle is loss-making, a P/E cannot be derived at all, so the approach of judging cheap or expensive by an earnings multiple does not hold. A P/B of 8.58x looks high on net assets alone, but for a clinical-stage biotech the share price pre-reflects future pipeline value rather than the assets it holds, so it is hard to declare it overvalued on P/B alone. Likewise, the trailing P/E based on last year's confirmed results is clearly limited because it is loss-making, and the forward P/E based on this year's estimate cannot be calculated because the timing of a swing to profit cannot be fixed by the company's own figures. Even compared against the same clinical-stage biotech group, the crux is not the multiple but the pace of clinical progress and out-licensing frequency; because such names have an asymmetric structure where value rises in steps on clinical success and drops sharply on failure, it is more appropriate to track clinical and deal events than to conclude from quantitative valuation alone. Therefore, with the information currently available, an inconclusive stance is reasonable.
Price history Close · MA20 · MA60
The latest close is ₩9,540 and the market capitalization is ₩211.4 billion. The price sits below its 20-day moving average (₩12,180) and below its 60-day moving average (₩13,914). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 32.8, a neutral level. The one-month change is -15.3%, the three-month change is -28.4%, and the position relative to the 52-week high is -51.6%. Relative strength versus the KOSDAQ is 86 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 87% of all stocks. Over the past three months it lagged the index by 6.3%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -6.27% / 6M +37.56% / 12M +77.17%
Key metrics vs sector median
Valuation
A net loss makes the P/E an unreliable valuation gauge. The P/B of 5.68x is below the sector median (7.05x).
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Profitability & financials
The operating margin is -232393.8%. The debt ratio is 143.5%, so the financial structure is moderate.
Growth FY2025 · annual report (separate)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $6.8M | $1.1M | $4,707 | -99.57% ↓ slower |
| Operating profit | -$7.0M | -$8.4M | -$10.9M | — |
| Net profit | -$7.7M | -$9.9M | -$12.0M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.1M | $2.4M | $6.8M | $1.1M | $4,707 |
| Operating profit | -$4.6M | -$7.9M | -$7.0M | -$8.4M | -$10.9M |
| Net profit | -$4.4M | -$7.6M | -$7.7M | -$9.9M | -$12.0M |
| Revenue CAGR | 4-yr avg -81.64% | ||||
Revenue fell 99.6% year over year (2023 ₩10.3 billion → 2024 ₩1.6 billion → 2025 ₩7,101,468), and the three-year trend is 'falling'. The rate of decline widened from the prior year. Operating results are in the red, so a swing back to profit matters more than the growth rate here. Over the 5 years on record, revenue compound annual growth (CAGR) is -81.6%. The two-year revenue CAGR is -97.4%.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.
Points to watch
- The most recent full year was a loss, so it is worth checking whether profitability recovers.
- Revenue fell 99.6% year over year (3-year trend: falling).
Recent news & events searched · sourced
- 2026-05-11FilingOut-licensing deal signed for the bispecific antibody MT-103 (material management matter relevant to investment judgment). The first external licensing result for its in-house antibody pipeline.Short term: positive for sentiment on expectations of upfront and milestone inflows. Medium term: secures a track record for commercializing the follow-on MT-201 and MT-202. Source
- 2026-06-05FilingAmendment to the material management matter relevant to investment judgment regarding the MT-103 out-licensing deal. Deal details were corrected and supplemented.Short term: clarification of the deal terms. Medium term: the timing of deal execution and follow-on milestone recognition needs to be confirmed. Source
- 2026-04-02EarningsDisclosure related to the Phase 2b clinical-study report (CSR) for the diabetic nephropathy drug CU011001. Secures later-stage clinical data for the kidney-indication candidate.Short term: share-price volatility widens depending on the trial results. Medium term: can be used as a card in the next trial and out-licensing negotiations. Source
- 2026-05-28UpdateDisclosure of the conversion-price adjustment for the first-series convertible bond. A factor that could increase the share count via new-share issuance upon conversion.Short term: a potential dilution factor. Medium term: the financing structure and future changes in share count need to be checked. Source
- 2026-03-26FilingStock-option grant filing. Intended to attract key personnel but carries the possibility of future new-share issuance.Short term: limited impact. Medium term: positive for talent retention while a potential dilution factor coexists. Source
Figure cross-check computed ↔ external
Recent filings
- 2026-06-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-10OwnershipOfficers'/major-shareholders' holdings report
- 2026-06-05Amended filing
- 2026-05-28Disclosure
- 2026-05-15PeriodicQuarterly report
- 2026-05-11Disclosure
- 2026-04-02Disclosure
- 2026-03-26Disclosure
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.